17 studies on Exenatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 17 dated studies on Exenatide. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clin…
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a n…
While specific findings are not yet available, this study's design is crucial for understanding the feasibility of transitioning Type 2 Diabetes patients to sustained-release GLP-1R agonist therapies. If ITCA 650 prov…
Understanding the interplay between GLP-1 RA therapy and cardiac biomarkers like NT-proBNP and hs-cTnT is crucial for refining cardiovascular risk stratification in Type 2 Diabetes. This research could help identify p…
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obe…
This Phase III comparative trial is significant because it directly compares three different GLP-1 RA formulations, potentially providing crucial data to guide treatment selection for obese patients. The findings coul…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This pilot study represents a novel approach to Type 2 Diabetes Mellitus management, focusing on an intensive, short-term intervention to potentially reverse or significantly improve disease progression. If successful…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
This study is crucial because it seeks to uncover a novel mechanism by which semaglutide promotes weight loss, specifically through its impact on brown adipose tissue (BAT). Understanding this pathway could lead to mo…
This comprehensive review underscores the significant potential of GLP-1 RAs as novel therapeutic agents for a range of psychiatric disorders, extending their utility beyond metabolic health. Their established safety …
This comprehensive review highlighted the diverse and innovative approaches being explored to combat obesity in the early 2000s. The identification of multiple drug classes, from central nervous system modulators to p…
Free, no account — handy when you're working with Exenatide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account